key: cord-0724601-buca7wug
authors: Limongelli, Giuseppe; Iucolano, Stefano; Monda, Emanuele; Elefante, Pasquale; De Stasio, Chiara; Lubrano, Imma; Caiazza, Martina; Mazzella, Marialuisa; Fimiani, Fabio; Galdo, Maria; De Marchi, Giulia; Esposito, Martina; Rubino, Marta; Cirillo, Annapaola; Fusco, Adelaide; Esposito, Augusto; Trama, Ugo; Esposito, Salvatore; Scarano, Gioacchino; Sepe, Joseph; Andria, Generoso; Orlando, Valentina; Menditto, Enrica; Chiodini, Paolo
title: Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry
date: 2021-05-13
journal: J Public Health (Oxf)
DOI: 10.1093/pubmed/fdab137
sha: 60877eba054f491b281076645f1a35e8449fe75a
doc_id: 724601
cord_uid: buca7wug

BACKGROUND: The aims of this study were: to investigate the capacity of the rare disease healthcare network in Campania to diagnose patients with rare diseases during the outbreak of Covid-19; and to shed light on problematic diagnoses during this period. METHODS: To describe the impact of the Covid-19 pandemic on the diagnosis of patients with rare diseases, a retrospective analysis of the Campania Region Rare Disease Registry was performed. A tailored questionnaire was sent to rare disease experts to investigate major issues during the emergency period. RESULTS: Prevalence of new diagnoses of rare disease in March and April 2020 was significantly lower than in 2019 (117 versus 317, P < 0.001 and 37 versus 349, P < 0.001, respectively) and 2018 (117 versus 389, P < 0.001 and 37 versus 282, P < 0.001, respectively). Eighty-two among 98 rare disease experts completed the questionnaire. Diagnostic success (95%), access to diagnosis (80%) and follow-up (72%), lack of Personal Protective Equipment (60%), lack of Covid-19 guidelines (50%) and the need for home therapy (78%) were the most important issues raised during Covid-19 outbreak. CONCLUSIONS: This study describes the effects of the Covid-19 outbreak on the diagnosis of rare disease in a single Italian region and investigates potential issues of diagnosis and management during this period.

The severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) has been declared a pandemic by the World Health Organization, emerging as a global threat due to the high transmission rate of the virus and the high number of deaths. 1, 2 The presentation of Covid-19 is extremely heterogeneous, ranging from the absence of symptoms to severe disease, including three phases (i.e. viral infection, pulmonary phase, hyperinflammatory illness/systemic phase). [3] [4] [5] [6] The exponential demand for hospitalization and emergency care has suddenly changed the priorities of healthcare systems around the world, and many hospitals have been dedicated to Covid-19 patients, in part or as a whole. 7, 8 At the same time, routine outpatient management of patients with chronic and rare diseases has been suspended in most hospitals. [7] [8] [9] With a prevalence of less than 1 in 2000 people, rare diseases affect more than 300 million people worldwide. 10 Compared with common diseases, such as diabetes or coronary artery disease, each rare disease affects a small number of people with specific issues related to their rarity, including the delayed clinical diagnosis, the paucity of expertise centers that often are at a great distance from patients' home, the absence of specific therapies, 10, 11 etc.

In response to the growing Covid-19 pandemic in Italy, the Italian government has imposed a national lockdown, limiting the movement of the population except for necessity, work and health circumstances. In Italy, the national lockdown started on 9 March 2020 and was extended several times, until 3 May 2020.

The effect of lockdown is expected to have a significant impact on the rare disease healthcare network and its capacity to diagnose and manage patients. Nevertheless, there is a lack of data in the literature on this topic.

The aims of this study were: to investigate the capacity of the rare disease healthcare network in Campania (southern Italy) to diagnose patients with rare disease during the outbreak of Covid-19; and to investigate the potential issues regarding patient diagnosis faced by rare disease healthcare experts in Campania.

Since 2001, Italy has had a structured system to provide health care to patients with rare diseases, based on the 2001 rare disease ruling (Decreto ministeriale n. 279), which promotes the development of Rare Diseases Registries (RDR) at a regional level, and linked to the National Registry of Rare Diseases. 12

To describe the impact of the Covid-19 pandemic on the diagnosis of patients with rare diseases, a retrospective analysis of the Campania Region RDR (CRRDR) was performed.

The CRRDR is part of a consortium called 'AREA VASTA', which includes eight Italian regions (Provincia Autonoma Trento, Provincia Autonoma Bolzano, Veneto, Emilia Romagna, Umbria, Campania, Puglia and Sardegna) and is coordinated by Veneto Region. All the entities included in the list of rare diseases of the national health system are present in the database with a specific code ('R' code) and clustered in 16 macro-groups (i.e. rare infective disease, rare metabolic disease, rare malformations, etc.). 12,13 This registry includes demographic and clinical information routinely collected by physicians of the Campania rare disease network and authorized to access the system by hospital managers (https://malattierare.rve.overnetwork.it/). The acquisition and management of the data comply with the EU 2016/679 General Protection Data Protection Regulation. 14 To investigate major and minor issues faced by the Campania rare disease network during the Covid-19 outbreak, a specific questionnaire was designed by GL, PC and SI (Table 1) .

Our research protocol adheres to the principles of the Declaration of Helsinki and its amendments and has been approved by the Ethical Committee of the AO Colli/Vanvitelli University (prot. n • AOC-0013766-2020; 08/05/2020).

All subjects with certified rare disease were included in the CRRDR. We have retrospectively analyzed all the new diagnoses obtained in the first four months of 2020 (January-April) and then compared the results with the diagnoses performed in the first four months of 2019 and 2018. Furthermore, a sub-analysis according to different rare disease macro-groups and/or for single disease/code was performed. Particular attention was given to the number of certificates of a rare disease issued in the first four months of 2020, comparing it with the first four months of 2019 and 2018.

A dedicated questionnaire (Table 1 ) was designed and sent by email to the physicians of the Campania rare disease network. To detect challenges in the diagnosis of rare diseases during the first four months of 2020 due to the Covid-19 pandemic, the questionnaire was sent only to physicians who issued a high number of certificates for rare disease in 2019 (i.e. > 5). Following this protocol, the questionnaire was sent to 98 specialists and 82 were completed. To facilitate compilation and to avoid misunderstanding, all the questions had binary or a limited set of options. 

Descriptive statistics were used to analyze different timeperiods of CRRDR and analyze answers to the questionnaire from the specialists of the rare disease network. Comparison of the number of certificates between time-periods was made by means of Poisson test. A P-value lower than 0.05 was considered statistically significant. Data were analyzed using R version 3.6.1 (R Foundation for Statistical Computing, Vienna, Austria).

The The prevalence of new diagnoses of rare diseases (i.e. certificates entered in the CRRDR) in the first four months of 2020 was significantly lower than 2019 (774 versus 1272; P < 0.001) and 2018 (774 versus 1294; P < 0.001) (Fig. 1) . This difference is mainly related to significantly fewer diagnoses clinched in March and April 2020, as no significant differences were found in January and Among the 11 hospitals included in the rare disease Campania network, we described the results of the six with the most certificates in the first four months of 2018 and 2019, to reduce variability related to the low number of diagnoses performed in the remaining hospital. In the first four months of 2020, except for Cardarelli hospital, all the hospitals had fewer certificates compared with 2018 and 2019, as shown in Fig. 2A . However, focusing on April, the decreased number of diagnoses in 2020 occurred for all six hospitals within the Campania network (Fig. 2B) .

Furthermore, we analyzed the number of certificates issued in the first four months of 2020 for each rare disease macrogroup and compared it with 2019 and 2018 (Fig. 3A ). Group 7 (diseases of central and peripheral nervous system) was the most prevalent macro-group in the 3-year period. Considering the first four months of the years, for all the 16 macro-groups, the number of certificates was lower in 2020 than in 2019 and 2018, with some exception (i.e. Group 11 [diseases of the digestive system]: 25 in 2020 versus 23 in 2018; Group 6 [diseases of the blood and blood-forming organs]: 91 in 2020 versus 89 in 2018; Group 3 [endocrine and nutritional diseases]: 76 in 2020 versus 37 in 2018). However, focusing on the month of April (Fig. 3B) , for all the macro-groups, the number of certificates in 2020 was lower than 2019 and Moreover, the number of certifications issued in April of the 3 years was also surveyed. As reported in Supplementary Table S1, we considered the rare diseases with the highest number of certificates in April 2018 and 2019 and compared it to April 2020. Overall, the number of certificates in April 2020 was significantly lower than April 2018 (28 versus 327) and 2019 (28 versus 299), and this finding was consistent for all the rare diseases (except for isolated deficiency of growth hormone: 3 in April 2018 versus 5 in April 2020).

The response rate to the survey administered to the rare disease experts of the Campania network was 83.7%. The questionnaire was sent to 98 specialists and 82 completed questionnaires were returned. The answers to the questionnaires are reported in Table 1 . Diagnostic success (95%), access to diagnosis (80%) and follow-up (72%), lack of Personal Protective Equipment (PPE) (60%), lack of Covid-19 guidelines (50%) and the need for home therapy (78%) were the most important issues raised during the Covid-19 outbreak.

The Covid-19 pandemic has created ongoing challenges for health systems worldwide, and in Italy, the decentralization and fragmentation of healthcare services have limited interventions and effectiveness. [1] [2] [3] [4] [5] [6] [7] [8] Furthermore, despite the steady march of progress in management strategies in the pre-vaccine era, the only effective measure to counteract the spread of Covid-19 was represented by regional or national lockdown. 15 Nevertheless, the reorganization of health systems, the national lockdowns and the fear of SARS-Cov-2 infection have kept most patients away from hospitals and have had negative effects on the diagnosis and management of acute and chronic disorders. 2, 7, 8, 9 For example, during the Covid-19 pandemic, there have been fewer hospitalizations for acute myocardial infarction 16 and a significant delay in the routine care for chronic disease, resulting in an increased number of complications. [17] [18] [19] Lack of knowledge and expertise often makes the diagnosis of rare disease a challenge, and an average time of 6 years from symptom onset to a specific diagnosis has been reported. 20 Thus, patients with a rare disease often face a 'diagnostic odyssey', typically receiving multiple and inconclusive diagnostic tests, misdiagnosis and incorrect treatments, that profoundly impact psychological wellbeing, clinical stability and socioeconomic costs. [21] [22] [23] The significant diagnostic delay often results in disease progression, resulting in an increased risk of disease complication and reduced efficacy of etiological treatments. 24

Covid-19 had a negative impact on the Campania Region's rare disease network, as seen in the CRRDR database. In particular, we observed a significant decline in certificates issued in March and April 2020 compared with the same two months of 2019 (less than 63 and 90%, respectively). These findings underline the real impact of Covid-19 on the diagnosis of rare diseases. As a consequence of the lockdown period, the conversion of many hospitals into Covid-19 dedicated units and the postponed 'elective' care, all 16 rare disease macro-groups experienced disruptions in diagnosis and management.

At the same time, scrutinizing the questionnaire uncovered a series of issues raised by the network specialists. The most affected activity was the 'first-access'. Specifically, the first evaluation of a patient with suspected rare disease was often postponed as a consequence of the less outpatient activity and elective care, or because patients refused the hospital admission for the fear of Covid-19 infection.

A national survey 25 was conducted by UNIAMO (Federazione delle Associazioni di Persone con Malattie Rare d'Italia, 23rd March-05th April) in collaboration with the 'Istituto Superiore della Sanita', about the needs of people with rare disease during the pandemic. In their survey, more than half of the interviewed patients suspended treatment against doctor's orders. In contrast, in our survey, most of the patients did not stop treatment. This difference is probably linked to the inconsistent way in which the answers were obtained (in the UNIAMO survey, they were completed by the patients themselves, while in the present survey, this was done by the healthcare professionals). Nevertheless, most of them preferred home therapy and, whenever possible, it was also encouraged by their doctors.

Home therapy/home delivery was assured for all patients, children and adults, requiring hospitalization for regular intravenous infusion (i.e. lysosomal storage disease). Indeed, home therapy was approved by the Italian Medicines Agency, providing the extension of therapeutic plans and encouraging home therapy when possible. In addition, a helpline was set up to assist patients with rare disease and immunosuppression.

This work presents several limitations. First, these results represent a narrow window into the region's healthcare and should now be compared with other experiences. Second, other factors, potentially responsible for a fall in certificates in March/April 2020, have not been investigated. Indeed, fewer certifications can be partially related to administrative obstacles during the Covid-19 pandemic (i.e. the trouble updating the rare disease registry). Third, the results of extraordinary measures (telephone support and home therapy/home delivery models) were not considered in the present study. Finally, not all the rare disease experts inside the regional network administered the questionnaire. However, more than twothird answered the questionnaire, and we think this can be representative of the regional situation.

In conclusion, this study depicts the effects of Covid-19 outbreak on diagnosis and management of rare diseases in a single Italian region. There were fewer diagnoses of rare disease during the outbreak period, and this was observed for all the hospital networks, the macro-groups and single rare diseases. A number of issues were raised (including diagnostic capacity, access to diagnosis and follow up, lack of PPE, etc.) by rare disease experts during the Covid-19 outbreak. Extraordinary measures, including telephone support and home therapy/home delivery, have been taken during the emergency phase, representing an example of how healthcare can potentially respond to the Covid-19 outbreak.

Supplementary data are available at the Journal of Public Health online.

A novel coronavirus emerging in China -key questions for impact assessment

Facing Covid-19 in Italy -ethics, logistics, and therapeutics on the Epidemic's front line

A novel coronavirus from patients with pneumonia in China

Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

The Natural History and Transmission Potential of Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Surgery scheduling in a crisis

Covid-19 Bergamo Hospital Crisis Unit. Adaptations and lessons in the province of Bergamo

The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET

RARE Diseases: Facts and Statistics

Disease control, civil liberties, and mass testing-calibrating restrictions during the Covid-19 pandemic

The Covid-19 pandemic and the incidence of acute myocardial infarction

COVID-19 pandemia and inherited cardiomyopathies and channelopathies: a short term and long term perspective

Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: the experience of a metabolic unit in Italy

Management of the patient with allergic and immunological disorders in the pandemic COVID-19 era

Diagnostic needs for rare diseases and shared prediagnostic phenomena: results of a German-wide expert Delphi survey

Health-related quality of life among adults with diverse rare disorders

Australian children living with rare diseases: experiences of diagnosis and perceived consequences of diagnostic delays

Can a decision support system accelerate rare disease diagnosis? Evaluating the potential impact of Ada DX in a retrospective study

An expert consensus document on the management of cardiovascular manifestations of Fabry disease

) of people with rare diseases in the current SARS-CoV-2 emergency scenario. Version of 30

Not applicable.

Not applicable.

The authors declare that they have no competing interests.

All data are incorporated into the article and its online supplementary material.